Login to Your Account



FDA in High Gear

No Holiday Cheer from Investors for Product Approval Milestones

By Peter Winter
BioWorld Insight Editor

Thursday, December 27, 2012
Like Rodney Dangerfield, biotech companies achieving FDA product approval milestones are not getting much respect from investors these days. Take the case of Aegerion Pharmaceuticals Inc., of Cambridge, Mass.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription